NDAINJECTIONINJECTABLEPriority Review
Approved
Oct 1988
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
3/8 — Basic
Priority Review
Drug data last refreshed 19h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SANDOSTATIN (octreotide acetate) is a somatostatin analog injectable small molecule approved in 1988 for acromegaly, carcinoid syndrome, and variceal bleeding. It works by mimicking somatostatin to inhibit hormone secretion and reduce blood flow in portal hypertension. The drug is administered via subcutaneous or intravenous injection.
$0.169BPart D
LOE ApproachingLOE approaching with low Part D spending signals a mature, niche product with limited growth prospects and likely stable, small team headcount.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Phase 1, Open-label, Drug-drug Interaction Study With Octreotide Acetate Injection and Telotristat Etiprate in Healthy Subjects
Started Jul 2014
24 enrolled
Drug Interactions
Sandostatin LAR and Axitinib vs Pbo in Pnts With Advanced Well-differentiated Non-pancreatic Neuroendocrine Carcinomas
Started Nov 2011
256 enrolled
Neuroendocrine TumorsAdvanced Cancer
Combination of Bevacizumab, Pertuzumab, and Sandostatin for Adv. Neuroendocrine Cancers
Started May 2010
43 enrolled
Neuroendocrine Carcinoma
Sandostatine® LP and Hyperinsulinism
Started May 2009
10 enrolled
Congenital Hyperinsulinism
Sandostatin for Patients With Androgen Independent Prostate Cancer
Started Jul 2007
13 enrolled
Prostate Cancer
Worked on SANDOSTATIN at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.